The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.
At the moment of publication, the compound presented is solely approved for use in the US by the US Food and Drug Administration (FDA) in chronic kidney disease (CKD) associated with type 2 diabetes (T2D). The compound is still being investigated for uses that have not been approved by the European Medicines Agency (EMA) and other health authorities.
European Association for the Study of DiabetesSymposium Sponsored by Bayer September 27 – October 1, 2021
Presentations of the Bayer Industry Symposium at the EASD 57th Annual Meeting 2021
Thank you for your interest! Please see below to download PDFs of the presentations of the Bayer Industry Symposium at the EASD 57th Annual Meeting 2021. Access to the presentations will be available after the congress presentation.
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Finerenone
Wednesday 29 September, 2021 | 18:35 - 18:45 CEST
New perspectives and interdisciplinary insights on the benefits of MR antagonism in CKD and T2D
Addressing unmet needs in CKD and T2D with nonsteroidal MR antagonists
Session: Industry SymposiumSpeaker: Roland Schmieder
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Wednesday 29 September, 2021 | 18:45 - 19:00 CEST
New perspectives and interdisciplinary insights on the benefits of MR antagonism in CKD and T2D
MR antagonism confers benefits irrespective of anti-diabetic agents or metabolic status: Insights from FIDELIO-DKD
Session: Industry SymposiumSpeaker: Paola Fioretto
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Wednesday 29 September, 2021 | 19:00 - 19:15 CEST
New perspectives and interdisciplinary insights on the benefits of MR antagonism in CKD and T2D
FIGARO-DKD: Expanding the benefit of MR antagonism in CKD and T2D
Session: Industry SymposiumSpeaker: Samy Hadjadj
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
MA-M_FIN-ALL-0525-1